Hybrid-Designed Inhibitors of p38 MAP Kinase UtilizingN-Arylpyridazinones

Imidazo[1,2-alpha]pyridyl N-arylpyridazinones were hybridized from the classic pyridinylimidazoles and the more recent dual hydrogen bond acceptors, resulting in a new structural class of selective p38 MAP kinase inhibitors.